{
  "abstract": "T-cell engagers (TCEs) have emerged as a promising tool to perform a ‘deep’ depletion of tissue B cells and plasma cells. Originally developed for the treatment of hematological diseases, TCEs have meanwhile proven effective in B cell-mediated autoimmune diseases such as systemic sclerosis and systemic lupus erythematosus (SLE).Learning Objectives At the end of this presentation participants will be able to:Describe the MOA of conventional therapeutic antibodies and TCEsDemonstrate current knowledge about the use of TCEs in the treatment of autoimmune diseases and in particular SLE",
  "authors": [
    {
      "affiliations": [
        "Charité University Hospital, Berlin"
      ],
      "name": "Gerhard Krönke"
    }
  ],
  "title": "24 T-cell engager experience in SLE",
  "uid": "cc642bea-b17e-5923-9ba0-0072cc98b105"
}